Replimune wins accelerated FDA approval for RP1 in advanced melanoma after two rejections, despite data concerns. Drug combines oncolytic virus with Opdivo.
Replimune finally has its eureka moment.
After two rejections, public clashing with the previous FDA leaders and a closed-door meeting with the White House, the …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Replimune rebounds to win FDA approval of melanoma drug
Replimune secures FDA approval for melanoma therapy Tudriqev after long regulatory battle
FDA approves Replimune melanoma drug previously rejected twice
FDA approves Replimune's Tudriqev melanoma drug on third try
FDA OKs accelerated approval to twice-rejected Tudriqev with Opdivo for advanced melanoma
FDA Finally OKs Twice-Rejected Melanoma Drug
The accelerated clearance follows two earlier rejections and the support of an advisory panel that disputed the arguments of FDA…
Replimune defends its single-arm RP1 melanoma trial data as an FDA advisory panel prepares to vote on whether results are…
Replimune will resubmit advanced melanoma drug RP1 to the FDA after two rejections, following the ouster of Commissioner Marty…
The positive vote came despite persistent concerns from FDA scientists and positions the company to bounce back from two earlier…
In a remarkable turnaround, Replimune has reversed the fortune of its melanoma therapy, winning FDA approval after two prior…
The FDA approved Replimune’s treatment for advanced melanoma, dealing the company and patient advocates a big win after a…
